Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. Its FORCE platform is designed to deliver functional improvement by targeting the root cause of disease, and the company is advancing programs for DM1, DMD, and FSHD.
Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.
The FDA has denied or discouraged at least eight drug applications in the past year, including treatments for rare diseases, raising concerns about regulatory consistency and the future of experimental therapies.
Dyne Therapeutics is preparing a U.S. Accelerated Approval submission for z-rostudirsen in Duchenne muscular dystrophy and gearing up for a Phase 3 trial of z-basivarsen in myotonic dystrophy, while scaling operations to support potential commercialization.
Japan's Ministry of Health, Labour and Welfare granted Orphan Drug designation to Dyne Therapeutics' investigational treatment zeleciment-basivarsen for myotonic muscular dystrophy type 1, adding to existing designations in the U.S. and Europe.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07486934 |
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 |
RECRUITING | PHASE3 |
| NCT05524883 |
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05481879 |
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 |
RECRUITING | PHASE1/PHASE2 |
| NCT04635891 |
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) |
RECRUITING | |
| NCT03458832 |
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD |
ACTIVE_NOT_RECRUITING |
